| [1] |
Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and Meta-analysis[J]. Hum Reprod Update, 2014, 20(5): 748-758.
|
| [2] |
Royal College of Obstetricians and Gynaecologists, British Society for Gynaecological Endoscopy. Management of endometrial hyperplasia (Green-top guideline No. 67)[M]. London: RCOG, 2016: 1-30.
|
| [3] |
Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome[J]. Hum Reprod, 2012, 27(5): 1327-1331.
|
| [4] |
Holm NS, Glintborg D, Andersen MS, et al. The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism[J]. Acta Obstet Gynecol Scand, 2012, 91(10): 1173-1176.
|
| [5] |
Li L, Zhang J, Deng Q, et al. Proteomic profiling for identification of novel biomarkers differentially expressed in human ovaries from polycystic ovary syndrome patients[J]. PLoS One, 2016, 11(11): e164538.
|
| [6] |
Li L, Mo H, Zhang J, et al. The role of heat shock protein 90B1 in patients with polycystic ovary syndrome[J]. PLoS One, 2016, 11(4): e152837.
|
| [7] |
Piltonen TT. Polycystic ovary syndrome: endometrial markers[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37(1): 66-79.
|
| [8] |
Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help[J]. Gynecol Oncol, 2013, 132(1): 248-253.
|
| [9] |
Fanta M. Is polycystic ovary syndrome, a state of relative estrogen excess, a real risk factor for estrogen-dependant malignancies[J]. Gynecol Endocrinol, 2013, 29(2): 145-147.
|
| [10] |
Lee DE, Park SY, Park SY, et al. Clinical and biochemical profiles according to homeostasis model assessment-insulin resistance (HOMA-IR) in Korean women with polycystic ovary syndrome[J]. J Menopausal Med, 2014, 20(3): 104-110.
|
| [11] |
Luo L, Xu L, Tang L．The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway[J]．Cancer Biomark, 2017, 21(1): 145-149.
|
| [12] |
Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers[J]. Oxid Med Cell Longev, 2016, 2016: 8589318.
|
| [13] |
Cavalieri EL, Rogan EG. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention[J]. Clin Transl Med, 2016, 5(1): 12.
|
| [14] |
Liu S, Hu L, Yang M. Research progress of the effects of environmental estrogens mediated by G protein-coupled estrogen receptor 1[J]. Asian J Ecotoxicol, 2016, 11(1): 52-60.
|
| [15] |
李金皎，段华. G蛋白偶联雌激素受体对细胞增殖调节的研究进展[J]. 中国计划生育和妇产科，2016, 8(2): 23-27.
|
| [16] |
Saczko J, Michel O, Chwikowska A, et al. Estrogen receptors in cell membranes: regulation and signaling[J]. Adv Anat Embryol Cell Biol, 2017, 227: 93-105.
|
| [17] |
MacLaughlan SD, Palomino WA, Mo B, et al. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium[J]. Obstet Gynecol, 2007, 110(1): 146-154.
|
| [18] |
宋振，高恒. CCN即早基因家族在脑胶质瘤发生机制中的研究进展[J]. 临床神经外科杂志，2014, 11(2): 153-155.
|
| [19] |
Hulchiy M, Nybacka A, Sahlin L, et al. Endometrial expression of estrogen receptors and the androgen receptor in women with polycystic ovary syndrome: a lifestyle intervention study[J]. J Clin Endocrinol Metab, 2016，101(2): 561-571.
|
| [20] |
Li X, Shao R. PCOS and obesity: insulin resistance might be a common etiology for the development of type Ⅰ endometrial carcinoma[J]. Am J Cancer Res, 2014, 4(1): 73-79.
|
| [21] |
Anagnostis P, Tarlatzis BC, Kauffman RP, et al. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences[J]. Metabolism, 2017, pii: S0026-0495(17)30274-3.
|
| [22] |
Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp[J]. Hum Reprod, 2013, 28(3): 777-784.
|
| [23] |
罗国群，邓伟芬，柳倩茹，等. PCOS患者子宫内膜病变和胰岛素受体表达的临床研究[J]. 中国计划生育学杂志，2013, 21(1): 32-35.
|
| [24] |
Li T, Mo H, Chen W, et al. Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome[J]. Reprod Sci, 2016, 24(5): 646-655.
|
| [25] |
Zhang HY, Zhang YF, Han YK, et al. Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients[J]. Chin J Obstet Gynecol, 2012, 47(1): 19-23.
|
| [26] |
Wang CF, Zhang G, Zhao LJ, et al. Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth[J]. PLoS One, 2013, 8(8): e69001.
|
| [27] |
Shafiee MN, Chapman C, Barrett D, et al. Reviewing the molecular mechanisms which increase endometrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): time for paradigm shift[J]. Gynecol Oncol, 2013, 131(2): 489-492.
|
| [28] |
Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability[J]. Cancer Discov, 2011, 1(2): 170-185.
|
| [29] |
Shafiee MN, Seedhouse C, Mongan N, et al. Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer[J]. Mol Cell Endocrinol, 2016, 424: 94-101.
|
| [30] |
De Marco P, Bartella V, Vivacqua A, et al. Insulin-like growth factor-Ⅰ regulates GPER expression and function in cancer cells[J]. Oncogene, 2013, 32(6): 678-688.
|
| [31] |
Oyama S, Izutsu T. Cell cycle analysis of endometrial cancer cells in vitro treated with growth factor and steroid hormone[J]. Hum Cell, 1992, 5(4): 363-371.
|
| [32] |
陈东思，刘建新，祁秀娟，等. IRS-1、ERK2蛋白表达及其丝氨酸磷酸化程度与PCOS患者胰岛素抵抗的关系[J]. 中华妇产科杂志，2016, 51(4): 293-295.
|
| [33] |
Song XR, Zhang HY, Zhang YF, et al. Extracellular signal-regulated protein kinase activation in endometrium with polycystic ovary syndrome and its significance[J]. Chin J Obstet Gynecol, 2010, 45(10): 767-771.
|
| [34] |
Holm NS, Glintborg D, Andersen MS, et al. The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism[J]. Acta Obstet Gynecol Scand, 2012, 91(10): 1173-1176.
|
| [35] |
Patlolla S, Vaikkakara S, Sachan A, et al. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance[J]. Gynecol Endocrinol, 2018, 34(3): 238-242.
|
| [36] |
张仁浇，刘宏伟，白怀，等. 氧化应激与多囊卵巢综合征雄激素增多症关系的研究现状[J/CD]. 中华妇幼临床医学杂志(电子版), 2017, 13(6): 633-639.
|
| [37] |
Zhao PL, Zhang QF, Yan LY, et al. Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases[J]. Asian Pac J Cancer Prev, 2014, 15(20): 8975-8979.
|
| [38] |
Piltonen TT. Polycystic ovary syndrome: Endometrial markers[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37: 66-79.
|
| [39] |
Li X, Pishdari B, Cui P, et al. Regulation of androgen receptor expression alters AMPK phosphorylation in the endometrium: in vivo and in vitro studies in women with polycystic ovary syndrome[J]. Int J Biol Sci, 2015, 11(12): 1376-1389.
|
| [40] |
陈欣，宋岩，邓永志，等. 慢性炎症因子参与多囊卵巢综合征发病的初步探讨[J]. 中国妇幼保健，2016, 31(22): 4635-4636.
|
| [41] |
王泽. 多囊卵巢综合征与慢性炎症因子[J]. 实用妇产科杂志，2014, 30(5): 339-341.
|
| [42] |
郑艳华，赖毛华，刘华，等. 慢性炎症及氧化应激与PCOS远期患病风险的研究进展[J]. 现代妇产科进展，2013, 22(8): 674-676.
|
| [43] |
Elfayomy AK, Almasry SM, Attia GM, et al. Enhanced expression of vascular endothelial growth factor and increased microvascular density in women with endometrial hyperplasia: a possible relationship with uterine natural killer cells[J]. Rom J Morphol Embryol, 2015, 56(2 Suppl): 725-734.
|
| [44] |
Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of inflammatory markers and the risk of endometrial cancer[J]. Eur J Cancer Prev, 2013, 22(4): 374-379.
|
| [45] |
Kubyshkin AV, Aliev LL, Fomochkina II, et al. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia[J]. Inflamm Res, 2016, 65(10): 785-794.
|
| [46] |
张争，张学红. 肥胖与多囊卵巢综合征的相关分析[J]. 国际生殖健康/计划生育杂志，2012, 31(4): 316-318.
|
| [47] |
Ojeda-Ojeda M, Martínez-García MÁ, Alpañés M, et al. Association of TLR2 S450S and ICAM1 K469E polymorphisms with polycystic ovary syndrome (PCOS) and obesity[J]. J Reprod Immunol, 2016, 113: 9-15.
|
| [48] |
邓祥云，高楠，盛修贵. 糖代谢异常与肥胖型子宫内膜癌发生及靶向治疗的研究进展[J]. 中华妇产科杂志，2015, 50(11): 871-874.
|
| [49] |
刘婷婷，张淑香，高维萍. 血清瘦素和胰岛素生长因子Ⅱ与子宫内膜癌的相关性研究[J/CD]. 中华妇幼临床医学杂志(电子版), 2013, 9(5): 650-652.
|
| [50] |
涂晓宇，孙兆贵. 瘦素-受体系统与多囊卵巢综合征相关性的研究[J]. 生殖与避孕，2015, 35(12): 867-872.
|
| [51] |
Liu Y, Lyu L, Xiao W, et al. Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation[J]. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(3): 365-370.
|